Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients

American Journal of Transplantation

Volumn 9, Issue 5, 2009, Pages 1142-1150

  Gerna, G ^a   Lilleri, D ^a   Rognoni, V ^a   Agozzino, M ^b   Meloni, F ^a   Oggionni, T ^a   Pellegrini, C ^a   Arbustini, E ^b   D'Armini, A M ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

BAL; HCMV; Lung transplant; Preemptive therapy; T cell reconstitution; Viral load

Indexed keywords

GANCICLOVIR; STEROID;

ADOLESCENT; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BLOOD TRANSFUSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE RESPONSE; LUNG INFECTION; LUNG LAVAGE; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SEROLOGY; SYSTEMIC DISEASE; THERAPY EFFECT; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REACTIVATION;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEART-LUNG TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; LUNG DISEASES; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PNEUMONIA, VIRAL; POSTOPERATIVE COMPLICATIONS; T-LYMPHOCYTES; YOUNG ADULT;

EID: 65249100197     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02616.x     Document Type: Article

References (27)

1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998 338 : 1741 1751.
2. Ljungman P, Griffiths P, Paya C. Definitions of HCMV infection and disease in transplant recipients. Clinical Infect Dis 2002 34 : 1094 1097.
3. Rubin RH. Preemptive therapy in immunocompromised hosts. New Engl J Med 1991 324 : 1057 1059.
4. Grossi P, Minoli L, Percivalle E, Irish W, Viganò M, Gerna G. Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients. Transplantation 1995 59 : 847 851.
5. Gerna G, Baldanti F, Torsellini M et al. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: A randomized study. Antivir Ther 2007 12 : 63 72.
6. Limaye AP, Bakthavatsalam R, Kim HW et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006 81 : 1645 1652.
7. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000 356 : 645 649.
8. Kusne S, Shapiro R, Fung J. Prevention and treatment of cytomegalovirus infection in organ transplant recipients. Transplant Infect Dis 1999 1 : 187 203.
9. Westall GP, Michaelidis A, Williams TJ, Snell JI, Kotsimbos TC. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: A longitudinal study of lung quantitative real-time PCR for monitoring clinical intervention in transplant recipients. J Infect Dis 2004 190 : 1076 1083.
10. Bauer CC, Jaksch P, Aberle SW et al. Relationship between cytomegalovirus DNA load in epithelial lining fluid and plasma in lung transplant recipients and analysis of coinfection with Epstein-Barr virus and human herpesvirus 6 in the lung compartment. J Clin Microbiol 2007 45 : 324 328.
11. Riise GC, Andersson R, Bergstrom T, Lundmark A, Nilsson FN, Olofsson S. Quantification of cytomegalovirus DNA in BAL fluid: A longitudinal study in lung transplant recipients. Chest 2000 118 : 1653 1660.
12. Chemaly RF, Yen-Lieberman B, Chapman J et al. Clinical utility of cytomegalovirus viral load in bronchoalveolar lavage in lung transplant recipients. Am J Transplant 2005 5 : 544 548.
13. + T-cell immunity in patients receiving solid organ transplantation. Am J Transplant 2006 6 : 2356 2364.
14. Gerna G, Revello MG, Percivalle E, Torsellini M. A 6-hour microneutralization assay for human cytomegalovirus antibody by using monoclonal antibodies. Serodiagn Immunother Infect Dis 1990 4 : 243 247.
15. Gerna G, Vitulo P, Rovida F et al. Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients. J Med Virol 2006 78 : 408 416. Erratum in: J Med Virol 2008; 80: 1869.
16. Gerna G, Revello MG, Percivalle E, Morini F. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol 1992 30 : 1232 1237.
17. Gerna G, Percivalle E, Torsellini M, Revello MG. Standardization of the human cytomegalovirus antigenemia assay by means of in vitro generated pp65-positive peripheral blood polymorphonuclear leukocytes. J Clin Microbiol 1998 36 : 3585 3589.
18. Morbini P, Arbustini E. In situ characterization of human cytomegalovirus infection of bronchiolar cells in human transplanted lung. Virchows Arch 2001 438 : 558 566.
19. + T cells by a novel method using monocyte-derived HCMV-infected immature dendritic cells. Eur J Immunol 2005 35 : 1795 1804.
20. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994 179 : 1109 1118.
21. + T cells. J Gen Virol 2005 86 : 275 284.
22. + T cell frequencies by flow cytometry: Evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest 1997 99 : 1739 1750.
23. Hodson EM, Jones CA, Webster AC et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: A systematic review of randomised controlled trials. Lancet 2005 365 : 2105 2115.
24. Zamora MR, Nicolis MR, Hodges TN et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004 4 : 1635 1642.
25. Kotsimbos ATC, Sinickas V, Glare EM et al. Quantitative detection of human cytomegalovirus DNA in lung transplant recipients. Am J Respir Crit Care Med 1997 156 : 1241 1246.
26. Westall GP, Michaelides AE, Williams TJ, Snell GI, Kotsimbos TC. Post-lung transplant bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics. Transplantation 2003 75 : 2064 2068.
27. Lilleri D, Baldanti F, Gatti M et al. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy of human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients. J Med Virol 2004 73 : 412 418.